Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy
Trial Parameters
Brief Summary
The primary objective of this study is to assess the major pathological response (MPR) rate and pathologic complete response (pCR) rate in stage IB-IIIA non-small cell lung cancer (NSCLC) treated with a low dose of neoadjuvant immunotherapy combined with platinum doublet.
Eligibility Criteria
Inclusion Criteria: * Able to provide a signed Informed Consent Form (ICF), indicating agreement to comply with the requirements and restrictions in the ICF and protocol. * Male or female, aged 18 years or older. * Diagnosed with non-small cell lung cancer (NSCLC) with clinical staging IB, II, or IIIA. * Receiving treatment at Hospital de Base. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment, with no decline from two weeks prior to the baseline period or the day of the first dose. * Tumor sample meets the following requirements: * Negative for EGFR gene expression. * Negative for ALK and ROS1 protein expression. * PD-L1 protein expression documented and assessable. * Tumor is considered resectable upon initial assessment by three thoracic oncology surgeons (IR, CM, and HN) following a multidisciplinary review. * Adequate organ and bone marrow function as defined below: * Hemoglobin: ≥ 9.0 g/dL\* * Absolute neutrophil count: ≥ 1.5 × 10\^9 /L\* * Pl